Literature DB >> 30608546

Effectiveness of Intensive Endoscopic Screening for Esophageal Cancer in China: A Community-Based Study.

Mengfei Liu1, Zhonghu He1, Chuanhai Guo1, Ruiping Xu2, Fenglei Li3, Tao Ning1, Yaqi Pan1, Yong Li1, Huirong Ding1, Li Zheng1, Yue Zhou1, Xiuyun Tian1, Wenjun Yang1, Xueqian Wang1, Fang Lu1, Yanyan Zhang1, Yiqiang Zhao1, Fangcen Guo1, Ke Chen1, Lei Gao1, Min Sun1, Ying Liu1, Fangfang Liu1, Dong Hang1, Na Shen1, Jingjing Li1, Zhongyao Xu1, Qiyan Wang1, Chanyuan Zhang1, Amir Abliz1, Qiuju Deng1, Xiang Li1, Zhen Liu1, Chaoting Zhang1, Wenqing Yuan1, Hui Wang1, Noel S Weiss4, Hong Cai1, Yang Ke1.   

Abstract

Evidence is required to evaluate the effectiveness of population-level endoscopic screening for esophageal cancer (EC). In this study, 5,632 permanent residents aged 25-65 years from 6 villages in Hua County, Henan Province, China, were defined as the screening cohort and were offered intensive endoscopic screening. Residents of all 914 remaining villages in Hua County were included as the control cohort, and age-sex standardization was used to calculate the expected numbers of EC and upper gastrointestinal (GI) tract cancer cases and deaths in the screening cohort. The effectiveness of screening was assessed by comparing observed numbers of cases and deaths with expected numbers after 9-year follow-up of these screened subjects (2007-2016). In the screening cohort, 23 upper GI cancers (including 16 ECs) and 10 upper GI cancer deaths (including 5 EC deaths) were identified, and 47% (standardized incidence ratio = 0.53, 95% confidence interval (CI): 0.33, 0.87) and 66% (standardized mortality ratio = 0.34, 95% CI: 0.14, 0.81) reductions in cumulative EC incidence and mortality were found. For upper GI cancers, incidence and mortality were lowered by 43% (standardized incidence ratio = 0.57, 95% CI: 0.38, 0.86) and 53% (standardized mortality ratio = 0.47, 95% CI: 0.25, 0.88), respectively. This study showed that upper GI tract endoscopy is an effective population-level screening test for EC in high-risk regions.
© The Author(s) 2019. Published by Oxford University Press on behalf of the Johns Hopkins Bloomberg School of Public Health. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  China; endoscopy; esophageal cancer; esophageal squamous cell carcinoma; population-based endoscopic screening

Mesh:

Year:  2019        PMID: 30608546     DOI: 10.1093/aje/kwy291

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  14 in total

1.  Urinary protein biomarker panel predicts esophageal squamous carcinoma from control cases and other tumors.

Authors:  Linlin Ji; Jianping Wang; Bo Yang; Jianping Zhu; Yini Wang; Jiaqi Jiao; Kai Zhu; Min Zhang; Liqiang Zhai; Tongqing Gong; Changqing Sun; Jun Qin; Guangshun Wang
Journal:  Esophagus       Date:  2022-07-06       Impact factor: 3.671

2.  Estimated Cost-effectiveness of Endoscopic Screening for Upper Gastrointestinal Tract Cancer in High-Risk Areas in China.

Authors:  Ruyi Xia; Hongmei Zeng; Wenjun Liu; Li Xie; Mingwang Shen; Peng Li; He Li; Wenqiang Wei; Wanqing Chen; Guihua Zhuang
Journal:  JAMA Netw Open       Date:  2021-08-02

3.  Identification of diagnostic markers and lipid dysregulation in oesophageal squamous cell carcinoma through lipidomic analysis and machine learning.

Authors:  Yuyao Yuan; Zitong Zhao; Liyan Xue; Guangxi Wang; Huajie Song; Ruifang Pang; Juntuo Zhou; Jianyuan Luo; Yongmei Song; Yuxin Yin
Journal:  Br J Cancer       Date:  2021-05-05       Impact factor: 7.640

4.  S1PR1 promotes proliferation and inhibits apoptosis of esophageal squamous cell carcinoma through activating STAT3 pathway.

Authors:  Yan Liu; Yingru Zhi; Haizhu Song; Mingzhu Zong; Jun Yi; Guoxin Mao; Longbang Chen; Guichun Huang
Journal:  J Exp Clin Cancer Res       Date:  2019-08-22

5.  Initial results from a multi-center population-based cluster randomized trial of esophageal and gastric cancer screening in China.

Authors:  Hongmei Zeng; Kexin Sun; Maomao Cao; Rongshou Zheng; Xibin Sun; Shuzheng Liu; Zhiyi Zhang; Yuqin Liu; Guizhou Guo; Guohui Song; Yigong Zhu; Xianghong Wu; Bingbing Song; Xianzhen Liao; Yanfang Chen; Mingyang Song; Edward Giovannucci; Guihua Zhuang; Wenqiang Wei; Wanqing Chen; Jie He
Journal:  BMC Gastroenterol       Date:  2020-11-24       Impact factor: 3.067

6.  Estimating cancer survival and prevalence with the Medical-Insurance-System-based Cancer Surveillance System (MIS-CASS): An empirical study in China.

Authors:  Hongrui Tian; Yanjun Hu; Qingxiang Li; Liang Lei; Zhen Liu; Mengfei Liu; Chuanhai Guo; Fangfang Liu; Ying Liu; Yaqi Pan; Isabel Dos-Santos-Silva; Zhonghu He; Yang Ke
Journal:  EClinicalMedicine       Date:  2021-02-24

7.  A nomogram for screening esophageal squamous cell carcinoma based on environmental risk factors in a high-incidence area of China: a population-based case-control study.

Authors:  Xiaorong Yang; Chen Suo; Tongchao Zhang; Xiaolin Yin; Jinyu Man; Ziyu Yuan; Hui Chen; Jingru Yu; Li Jin; Xingdong Chen; Ming Lu; Weimin Ye
Journal:  BMC Cancer       Date:  2021-03-31       Impact factor: 4.430

8.  Development and Validation of an Esophageal Squamous Cell Carcinoma Risk Prediction Model for Rural Chinese: Multicenter Cohort Study.

Authors:  Junming Han; Lijie Wang; Huan Zhang; Siqi Ma; Yan Li; Zhongli Wang; Gaopei Zhu; Deli Zhao; Jialin Wang; Fuzhong Xue
Journal:  Front Oncol       Date:  2021-08-30       Impact factor: 6.244

9.  Development and external validation of a nomogram to predict the risk of Upper gastrointestinal precancerous lesions in a non-high-incidence area.

Authors:  Hai-Fan Xiao; Shi-Peng Yan; Ji-Gang Li; Zhao-Hui Shi; Yan-Hua Zou; Ke-Kui Xu; Xian-Zhen Liao
Journal:  Cancer Med       Date:  2020-09-16       Impact factor: 4.452

10.  CtBP2 interacts with TGIF to promote the progression of esophageal squamous cell cancer through the Wnt/β‑catenin pathway.

Authors:  Qianqian Ju; Maorong Jiang; Wenxin Huang; Qingbo Yang; Zhenghong Luo; Hui Shi
Journal:  Oncol Rep       Date:  2021-12-08       Impact factor: 3.906

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.